Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drug Safety Oversight Board Will Include VA, Other Agencies

This article was originally published in The Pink Sheet Daily

Executive Summary

The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.

Related Content

FDA's Drug Safety Oversight Board Looks To Promote Its Value
Drug Safety Oversight Efforts Paying Off, CDER’s Galson Says
Vioxx Promotions, Labeling Revisions Are Focus Of Drug Safety Hearing
Drug Safety System Will Be Improved By Medicare Rx, HHS Secretary Tells PhRMA
FDA’s Kweder Among Witnesses At Senate Drug Safety Hearing March 1
Post-Marketing Studies For All Products Endorsed By Drug Safety Expert
Drug Safety Legislation Unlikely, BIO CEO Greenwood Says
FDA Drug Safety Reform Must Come From Outside Agency – Sen. Grassley
“Drug Watch” Website Included In FDA’s Rx Safety Reforms
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts